Company profile
ARMATA PHARMACEUTICALS, INC.
AMEX:ARMPBiotechnology: Biological Products (No Diagnostic Substances)
Drug pipeline (1)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| C16G2 | phase2 | — | 5 | no active trials |
Revenue is the latest quarter the company reported for that product, from SEC filings; a fourth quarter is the year less nine months when no filing states one. Trial counts are of the product's ingredients, deduplicated by trial, so products sharing an ingredient share trials.
Clinical trials (11)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT03196219 | phase2 | completed | 2017-07-07 | 2017-11-22 | Armata Pharmaceuticals, Inc. | A Phase 2 Study to Evaluate the Microbiology, Safety and Tolerability of C16G2 Varnish and Strip in Adolescent and Adult Subjects |
| NCT03052842 | phase2 | completed | 2017-02-09 | 2017-04-05 | Armata Pharmaceuticals, Inc. | A Study to Evaluate the Microbiology, Safety and Tolerability of C16G2 Dental Strip Application |
| NCT03004365 | phase2 | completed | 2017-01-27 | 2017-03-29 | Armata Pharmaceuticals, Inc. | A Study to Evaluate the Safety and Microbiology of C16G2 Varnish Administered in Multiple Doses to Dental Subjects |
| NCT02757755 | phase1 | completed | 2016-05-01 | 2016-08-01 | Armata Pharmaceuticals, Inc. | Ascending Dose Study of the Safety of AB-SA01 When Topically Applied to Intact Skin of Healthy Adults |
| NCT04596319 | phase1_2 | completed | 2020-12-22 | 2022-12-14 | Armata Pharmaceuticals, Inc. | Ph 1/2 Study Evaluating Safety and Tolerability of Inhaled AP-PA02 in Subjects With Chronic Pseudomonas Aeruginosa Lung Infections and Cystic Fibrosis |
FDA applications (0)
No records yet.